98%
921
2 minutes
20
Juvenile myelomonocytic leukemia is an aggressive myeloproliferative disorder characterized by malignant transformation in the hematopoietic stem cell compartment with proliferation of differentiated progeny. Seventy-five percent of patients harbor mutations in the NF1, NRAS, KRAS, or PTPN11 genes, which encode components of Ras signaling networks. Using single nucleotide polymorphism arrays, we identified a region of 11q isodisomy that contains the CBL gene in several JMML samples, and subsequently identified CBL mutations in 27 of 159 JMML samples. Thirteen of these mutations alter codon Y371. In this report, we also demonstrate that CBL and RAS/PTPN11 mutations were mutually exclusive in these patients. Moreover, the exclusivity of CBL mutations with respect to other Ras pathway-associated mutations indicates that CBL may have a role in deregulating this key pathway in JMML.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2738571 | PMC |
http://dx.doi.org/10.1182/blood-2009-01-198416 | DOI Listing |
Asian J Endosc Surg
September 2025
Department of Hematology and Oncology, Shizuoka Children's Hospital, Shizuoka, Japan.
Introduction: Total splenectomy in children increases the risk of overwhelming post-splenectomy infection (OPSI). Laparoscopic subtotal splenectomy (LSS) is a technique to preserve splenic function while managing disease burden in pediatric hematologic disorders.
Materials And Surgical Technique: Three children aged 4 to 9 years with juvenile myelomonocytic leukemia (JMML) or hereditary spherocytosis underwent LSS.
Br J Haematol
August 2025
Department of Pediatric Oncology, National Cancer Institute Cairo University, Cairo, Egypt.
Juvenile myelomonocytic leukaemia (JMML) is a rare haematological malignancy caused by mutations in the Ras signalling pathway. Next-generation sequencing (NGS) and DNA methylation profiling used for diagnostic and risk stratification purposes are now standard of care in Europe and the United States for patients with JMML. To better understand how implementing these types of technologies would impact the treatment of JMML patients in different settings, molecular profiling was performed on 81 patients treated for JMML in Egypt from 2009 to 2022.
View Article and Find Full Text PDFPediatr Blood Cancer
August 2025
Department of Pediatric Hematology and Oncology, University of Freiburg, Freiburg, Germany.
Juvenile myelomonocytic leukemia (JMML) is a rare pediatric malignancy without defined environmental triggers. We report two cases of JMML with identical somatic PTPN11 mutations in children exposed in utero to thiopurine-containing chemotherapy. One mother underwent antileukemic treatment including thioguanine during early pregnancy; the other received 6-mercaptopurine for Crohn's disease throughout gestation.
View Article and Find Full Text PDFCell Death Differ
August 2025
Department of Hematology, National and Local Joint Engineering Research Center of Biodiagnosis and Biotherapy, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
The N6-methyladenosine (m6A) modification plays an important role in the pathogenesis of various myeloid malignancies. However, its specific role in RAS mutation-induced myeloid malignancy is incompletely understood. In this study, we found that m6A methyltransferase methyltransferase-like 14 (METTL14) was highly expressed and associated with a shorter survival in a RAS-mutation myeloid malignancy, juvenile myelomonocytic leukemia (JMML).
View Article and Find Full Text PDFTransl Pediatr
July 2025
Department of Hematopoietic Stem Cell Transplantation, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Background: , an oncofetal RNA-binding protein regulating stem cell self-renewal and oncogenic signaling via let-7 miRNA suppression, is implicated in diverse malignancies but remains poorly characterized in juvenile myelomonocytic leukemia (JMML). Despite its reported overexpression in approximately 50% of JMML cases, the epigenetic mechanisms driving dysregulation and its clinical relevance for risk stratification are undefined. Therefore, this study aimed to elucidate the epigenetic regulation of in JMML, and determine its potential as a biomarker for risk stratification.
View Article and Find Full Text PDF